Equities

Ibio Inc

Ibio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.45
  • Today's Change0.26 / 11.87%
  • Shares traded150.89k
  • 1 Year change-54.05%
  • Beta-3.3453
Data delayed at least 15 minutes, as of Nov 22 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 2 analysts offering 12 month price targets for Ibio Inc have a median target of 4.30, with a high estimate of 5.00 and a low estimate of 3.60. The median estimate represents a 96.35% increase from the last price of 2.19.
High128.3%5.00
Med96.3%4.30
Low64.4%3.60

Earnings history & estimates in USD

On Nov 12, 2024, Ibio Inc reported 1st quarter 2025 losses of -0.46 per share.
The next earnings announcement is expected on Feb 07, 2025.
Average growth rate+66.57%
Ibio Inc reported annual 2024 losses of -6.50 per share on Sep 20, 2024.
Average growth rate-54,398.26%
More ▼

Revenue history & estimates in USD

iBio, Inc. did not report revenues for the 1st quarter 2025. However, during the 1st quarter of the prior year the company reported revenues of 175.00k.
Average growth rate-33.33%
iBio, Inc. had revenues for the full year 2024 of 225.00k.
Average growth rate-18.25%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.